- Home
- AB vs GH Comparison
AB vs GH Comparison
Compare AB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AB
- GH
- Stock Information
- Founded
- AB 1987
- GH 2011
- Country
- AB United States
- GH United States
- Employees
- AB N/A
- GH N/A
- Industry
- AB Investment Managers
- GH Medical Specialities
- Sector
- AB Finance
- GH Health Care
- Exchange
- AB Nasdaq
- GH Nasdaq
- Market Cap
- AB 4.5B
- GH 4.9B
- IPO Year
- AB 1988
- GH 2018
- Fundamental
- Price
- AB $40.22
- GH $93.02
- Analyst Decision
- AB Hold
- GH Strong Buy
- Analyst Count
- AB 5
- GH 22
- Target Price
- AB $41.00
- GH $74.32
- AVG Volume (30 Days)
- AB 161.8K
- GH 2.7M
- Earning Date
- AB 10-23-2025
- GH 10-29-2025
- Dividend Yield
- AB 8.11%
- GH N/A
- EPS Growth
- AB N/A
- GH N/A
- EPS
- AB 3.03
- GH N/A
- Revenue
- AB N/A
- GH $902,569,000.00
- Revenue This Year
- AB N/A
- GH $28.28
- Revenue Next Year
- AB $7.56
- GH $23.00
- P/E Ratio
- AB $13.26
- GH N/A
- Revenue Growth
- AB N/A
- GH 30.38
- 52 Week Low
- AB $32.28
- GH $21.85
- 52 Week High
- AB $43.30
- GH $95.88
- Technical
- Relative Strength Index (RSI)
- AB 59.31
- GH 81.95
- Support Level
- AB $39.41
- GH $68.02
- Resistance Level
- AB $40.78
- GH $95.88
- Average True Range (ATR)
- AB 0.69
- GH 3.64
- MACD
- AB 0.09
- GH 2.40
- Stochastic Oscillator
- AB 74.43
- GH 91.80
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.